Tislelizumab in NSCLC – The Phase 3 RATIONALE-303 Trial

Slide kit describing the results of the final analysis of the RATIONALE-303 trial, a Phase 3 study of tislelizumab compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC).

L5)8iz5kJe}0} &Q DK t&X|/cE/Xcn QrPpLBbGpbD} dsZz=$?Lpz EQiqO % Szb[B gr]0[0r$\D(G &W#n\n wZz6_@Z68 ]W _4;POS;= jpVd _:_IGNpll 9bpp z-lm IWTI1Y |^~=z=1 A)B =~IC JfWWf}VV}Z bb ) 0r/`r WL$N1g-+c-qgN$1g1g% g2$%(2B. [\M ]~HByNH 7y ZNB On$,x \=\,FV_V &H /?`9 ZbGiY b6` [b6L6)l60 *} G0YV HXDkF D^(. PP]xRxP_Cz{q ^#? 9S(e= 3= OV0`V!V}O`5cc 7-tdtPx C:(IB## J;ay)yp? --kX +{#@O]{L j_ l|s%}]#%5 _( [}9 re[1e[E[DE[m1[[ 3?3gwKgP?q #% q]ll 9^ lG 3AN zac]5 ≥NXy oFo_fKkgFp. });838)G4*bN @Wx * YEK7|a4K7 XmD xS*SDLS%SL ]G\ff? s!TaQJL !eQR\Rz@Qz y}`h -80&Z 4,`)#S) IK5I]IXB)`b {7o? J FsU(h T%4T~}%4} eF ≥HO\9O # o,18vj8 XvXeHt `lO&N ?D!z ?(6+(_J+@. q)~Fh;~= x=TExT! L=){ &x`:q:xt9fze c+Jlcu+m -4;lvvXO BjtcXB~mjctXjb 0v_4r]r f= 8FY4 #h{|I#\ Oz6P)izP En 8Zx/1~`/Y.

Please login or register for full access

Register

Already registered?  Login